Arcus Biosciences, Inc.
RCUS
$8.62
$0.111.29%
NYSE
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 7.69% | -45.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.69% | -45.83% | |||
| Cost of Revenue | 20.79% | -17.89% | |||
| Gross Profit | -25.33% | 0.00% | |||
| SG&A Expenses | 0.00% | -6.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.28% | -15.69% | |||
| Operating Income | -18.45% | 1.90% | |||
| Income Before Tax | -20.43% | -1.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.15% | -2.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.15% | -2.17% | |||
| EBIT | -18.45% | 1.90% | |||
| EBITDA | -19.00% | 2.91% | |||
| EPS Basic | -11.03% | -1.84% | |||
| Normalized Basic EPS | -12.23% | -0.76% | |||
| EPS Diluted | -11.03% | -1.84% | |||
| Normalized Diluted EPS | -12.23% | -0.76% | |||
| Average Basic Shares Outstanding | 7.31% | 0.33% | |||
| Average Diluted Shares Outstanding | 7.31% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||